| Business Summary | | Bigmar,
Inc.
manufactures
generic
oncology
pharmaceuticals
and
related
products
(Oncology
Products)
and
intravenous
infusion
solutions
through
its
subsidiaries,
and
markets
these
products
in
Europe,
the
United
States
and
other
countries
primarily
through
pharmaceutical
distributors.
The
Company
has
three
wholly
owned
subsidiaries.
Bioren
SA
is
engaged
in
manufacturing
and
marketing
various
pharmaceutical
products
in
Switzerland.
Products
include
22
types
of
intravenous
infusion
solutions
and
other
related
products.
Bigmar
Pharmaceuticals
SA
manufactures
and
markets
Oncology
Products
such
as
Calcium
Leucovorin,
Sodium
Folinate,
Dacarbazine,
Doxorubicin,
Etoposide,
Fluorouracil,
Daunorubicin,
Methotrexate
and
Cisplatin.
The
Oncology
Products
are
marketed
in
the
United
States,
Italy,
Germany,
Switzerland,
Brazil,
Greece
and
Spain.
Bigmar
Therapeutics
is
essentially
a
shell
company
and
had
no
significant
business
operations,
as
of
December
31,
2000. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | BGMR
is
engaged
in
the
manufacturing
and
marketing
of
pharmcueticals
products
in
Switzerland.
Current
products
include
22
types
of
intravenous
infusion
solutions
and
other
related
products.
For
the
three
months
ended
3/31/01,
revenues
rose
29%
to
$2.3
million.
Net
loss
before
extraordinary
item
remained
flat
at
$1.3
million.
Revenues
reflect
increased
sales
volumes
in
European
markets.
Net
loss
was
partially
offset
by
decreased
R&D
expenses. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
2,200;
after
tax
earnings
were
-1,497. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| John Tramontana, 54 Chairman,
CEO | $207K | Cynthia May, 48 Pres,
Director | -- | Bernard Kramer, 46 COO,
VP, Director | -- | Massimo Pedrani, 45 Exec.
VP of R&D | -- | Declan Service, 40 VP-Bus.
Devel., Director | -- | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|